Key result
Evinacumab provides effective LDL-C lowering in patients with homozygous familial hypercholesterolemia.
Why the study?
Familial hypercholesterolemia is an underdiagnosed disease contributing to premature ASCVD, requiring review of management and emerging therapies such as evinacumab for nonresponders with homozygous familial hypercholesterolemia.
Evinacumab represents a novel and effective therapeutic option for significantly lowering lipid parameters in patients with homozygous familial hypercholesterolemia who do not adequately respond to standard therapies.
Answers are grounded in this paper and cite their sources.
Supports evinacumab consideration in refractory HoFH; extends ANGPTL3 inhibition data but leaves cardiovascular outcomes open.
Familial hypercholesterolemia (FH) is an underdiagnosed disease that contributes to a significant number of cardiovascular incidents through high serum Low-Density Lipoprotein Cholesterol (LDL-C) values. Its treatment primarily requires healthy lifestyle and therapy based on statins, ezetimibe and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); however, there are also new treatment options that can be used in patients who do not respond to therapy, among which we highlight evinacumab. Elevated LDL-C values, together with clinical manifestations associated with cholesterol deposition (e.g., tendon xanthomas, xanthelasma and arcus cornealis) and family history are the main elements in the diagnosis of FH. Pathognomonic signs of FH include extensor tendon xanthomas; however, their absence does not exclude the diagnosis. Elevated LDL-C levels lead to premature Atherosclerotic Cardiovascular Disease (ASCVD), which is why early diagnosis and treatment of FH is essential. Evinacumab, a novelty in pharmacological practice, having a complex mechanism of action, causes desirable changes in lipid parameters in patients with homozygous form of familial hypercholesterolemia (HoFH). This review collects and summarizes the most important aspects of the new drug, especially being a discovery in the treatment of HoFH, giving these patients hope for a longer and more comfortable life.
No takes yet. Share an insight, caveat, or question.
Krzemińska et al. (2022) conducted a review in Familial Hypercholesterolemia. Evinacumab was evaluated. Evinacumab, a monoclonal antibody against ANGPTL3, provides a novel and effective treatment option for lowering LDL-C in patients with homozygous familial hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: